New triple therapy shows promise for aggressive lung cancer
NCT ID NCT04660097
First seen Apr 14, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tested a combination of two drugs (durvalumab and anlotinib) plus standard chemotherapy as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. The goal was to see if this triple therapy could delay cancer growth better than chemo alone. 34 adults with good performance status took part in this single-arm phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China
-
Sixth People's Hospital of Luoyang
Luoyang, Henan, 471000, China
Conditions
Explore the condition pages connected to this study.